Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia-Reference-Cited by-同舟云学术

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia

Published:2014-01 Issue:1 Volume:35 Page:143-151
ISSN:0197-4580
Container-title:Neurobiology of Aging
language:en
Short-container-title:Neurobiology of Aging

Author:

Trzepacz Paula T.,Yu Peng,Sun Jia,Schuh Kory,Case Michael,Witte Michael M.,Hochstetler Helen,Hake Ann

Funder

Eli Lilly and Company

ADNI

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

Abbott

Alzheimer's Association

Alzheimer's Drug Discovery Foundation

Amorfix Life Sciences Ltd

AstraZeneca

Bayer HealthCare

BioClinica, Inc

Biogen Idec Inc

Bristol-Myers Squibb Company

Eisai Inc

Elan Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Genentech, Inc

GE Healthcare

Innogenetics, N.V.

IXICO Ltd

Janssen Alzheimer Immunotherapy Research & Development, LLC

Johnson & Johnson Pharmaceutical Research & Development LLC

Medpace, Inc

Merck & Co, Inc

Meso Scale Diagnostics, LLC

Novartis Pharmaceuticals Corporation

Pfizer Inc

Servier

Synarc Inc

Takeda Pharmaceutical Company

Canadian Institutes of Health Research

Foundation for the National Institutes of Health

NIH

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Developmental Biology,Clinical Neurology,Ageing,General Neuroscience

Reference43 articles.

1. Alzheimer's Association. 2012. Alzheimer's Disease Facts and Figures. Available at: http://www.alz.org/downloads/facts_figures_2012.pdf.

2. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease;Albert;Alzheimers Dement.,2011

3. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease;Brys;J. Alzheimers Dis.,2009

4. Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative;Chen;NeuroImage,2010

5. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?;Chételat;Neurology,2003

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 18F-FDG-PET-based deep learning for predicting cognitive decline in non-demented elderly across the Alzheimer’s disease clinical spectrum;Radiology Advances;2024-08-10

2. Utilizing Deep Learning for Diagnosing Radicular Cysts;Diagnostics;2024-07-06

3. Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease;Scientific Reports;2024-06-19

4. The use of individual-based FDG-PET volume of interest in predicting conversion from mild cognitive impairment to dementia;BMC Medical Imaging;2024-03-28

5. Deep learning for unsupervised domain adaptation in medical imaging: Recent advancements and future perspectives;Computers in Biology and Medicine;2024-03